Physician profile
Morgan E Mills
NPI 1669203121
$2,782.74
in general payments reported to CMS, 2019-2025
15 companies · $2,287 in 2025
The $2,287 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $495 · 2025: $2,287.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,619 · Education: $163.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,619.27 |
| Education | $163.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $725.76 | 2024-2025 | Tremfya, Stelara, Simponi Aria |
| Lilly USA, LLC | $369.52 | 2024-2025 | Omvoh |
| Abbvie INC. | $365.54 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $273.68 | 2025 | Entyvio |
| Pfizer INC. | $200.01 | 2025 | |
| Enterra Medical, INC. | $159.52 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $156.20 | 2025 | Dupixent |
| Ardelyx, INC. | $125.53 | 2025 | Ibsrela |
| Genzyme Corporation | $121.07 | 2024-2025 | |
| Merit Medical Systems INC | $104.26 | 2025 | Esophyx |
| Madrigal Pharmaceuticals | $76.60 | 2024-2025 | Rezdiffra, Resmetirom |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $41.48 | 2024-2025 | Xifaxan |
| Phathom Pharmaceuticals, INC. | $34.03 | 2024-2025 | Voquezna |
| Boston Scientific Corporation | $19.06 | 2024 | Patientcare Link |
| Janssen Pharmaceuticals, INC | $10.48 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Morgan Mills listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.